Business Wire · EVO · November 4, 2026

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

Get the app for more

Explore stock news, insights and company research.